Development of a C3 humanized rat as a new model for evaluating novel C3 inhibitors
Introduction: C3 is central for all complement activation pathways, thus an attractive therapeutic target. Many C3-targeted agents are under extensive development with one already approved for clinical use. However, most, if not all, C3 inhibitors are human or non-human primate C3-specific, making...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-11-01
|
| Series: | Journal of Innate Immunity |
| Online Access: | https://beta.karger.com/Article/FullText/534963 |